OBJECTIVE: To observe the effect of the polyglycol (PEG) modification of trimeric ? peptide(?3) on it’s anti-metastasis ability. METHODS: Using adhesion test to study the effects of ?3 and ?3-PEG on the adhesion of tumor cells to FN. Using artificial basal membrane to study the effects of ?3 and ?3-PEG on the invasion and recombination of basal membrane of tumor cells. RESULTS: Comparing to negative control,?3 and ?3-PEG could both inhibit the adhesion of SMMC-7721 and HCCLM6 tumor cells to FN with time-dependently(P

Female ; Humans ; Maternal Health Services ; Maternal Mortality ; Pregnancy

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; complications ; Humans ; Thromboembolism ; etiology ; prevention & control

China ; Dyslipidemias ; prevention & control ; Guidelines as Topic ; Humans

BACKGROUND:It is reported that vitamin C can induce bone marrow mesenchymal stem cel s differentiating into osteoblasts, and promote bone repair and regeneration. However, vitamin C solution is unstable, so a carrier is necessary. OBJECTIVE:To observe the loading and control ed-release abilities of calcium phosphate used as the carrier ofvitamin C. METHODS:Calcium phosphate particles loaded with vitamin C were fabricated using chemical precipitation method, and the final concentration of vitamin C was 0, 0.1, 2 and 4 mmol/L, respectively. The drug-loaded capacity was detected. The release of vitamin from calcium phosphate nanoparticles in the simulate body fluid and ultrasonic environment was respectively evaluated. MC3T3-E1 cel s were co-cultured with calcium phosphate nanoparticles loaded with 2 mmol/L vitamin C, or calcium phosphate nanoparticles only. The cel proliferation was detected at 1, 3, 5 and 7 days of culture, and the alkaline phasphatase activity was detected at 1, 5, 10 and 15 days of culture. RESULTS AND CONCLUSION:The drug-loaded contents of calcium phosphate nanoparticles loading 0, 0.1, 2 and 4 mmol/L vitamin C were (59.9±5.4)%, (87.2±1.2)%and (28.4±26.3)%, respectively. Under normal environment, al samples could release vitamin C persistently, but the initial release speed of the particles carrying 0.1 and 2 mmol/L vitamin C was lower than that of particles carrying 4 mmd/L vitamin. Under ultrasonic environment, 2 mmol/L vitamin C-loaded calcium phosphate particles exhibited a quick release speed firstly that reached 5-15%, fol owed by a slow release speed. When ultrasonic powers kept at 75, 105 and 150 W, the release duration of vitamin C was 220, 340 and 260 minutes, respectively. MC3T3-E1 cel proliferation did not change after co-cultured with 2 mmol/L vitamin C-loaded calcium phosphate particles but the alkaline phosphatase activity was improved. These results suggest that calcium phosphate particles can be used as the carrier of vitamin C.

Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma (B-NHL),but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug.Recently,many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma.The advances in translational research field were summarized in this manuscript.

Tremendous success has emerged in chimeric antigen receptor (CAR)-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin's lymphomas (NHLs). MCL comprises distinct subtypes with different pathological characteristics and clinical features. However, MCL remains incurable by intensified first-line regimens con-taining cytarabine and involving consolidation with high-dose therapy and autologous stem cell transplantation. Recently discovered somatic mutations and aberrant intracellular signaling pathways have been demonstrated to play an essential role in the pathogenesis of MCL. The related novel therapeutics, such as Btk inhibitors, PI3K inhibitors, and immune modulators, have exhibited promising ther-apeutic effects on untreated or even relapsed/refractory MCL. The development of an efficient combination therapy is urgently need-ed to improve the survival of MCL patients in the future.

Advances in clinical transformation research has facilitated discovery of a number of novel somatic mutations and aberrant intracellular signaling pathways involved in malignant proliferative B-cell lymphoma.Meanwhile,small molecular inhibitors targeting those mutation genes or signaling pathways have also been shown to be effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma.This paper reviewed important discoveries in clinical transformation research in lymphoma field in 2013.

About the malignant tumor in China,the hepatocellular carcinoma mortality is second only to lung cancer and serious threat to the life and health of the masses.Furthermore,because most patients has been in advanced cancer during medical treatment,so had lost the chance of one-stage surgical resection.However,the sensitivity of hepatocellular carcinoma to chemotherapy,radiotherapy and other treatments are poor.Transcatheter arterial chemoembolization is the main method of the treatment for patients those have lost the chance of operation,though the clinical effect is significant,the inadequate is also presence,such as tumor necrosis,incompletely clear,residual tumor nidus and the damage of the immune function after operation.Recombinant adenovirus p53 gene can validly infect tumor cells,transcription and expression of p53 protein,it also regulate the expression of related genes inhibiting tumor cell growth and induce cell apoptosis directly or indirectly.It is increasingly highly attention that recombincanting rAd-p53 with transcatheter arterial chemoembolization(TACE) to treat hepatocellular carcinoma.In order to evaluate the clinical value and promising future,we will make a brief summary for the research progress in this area in recent years.